+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bronchodilators Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Bronchodilators Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Bronchodilators Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6084105
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bronchodilators Market grew from USD 19.20 billion in 2024 to USD 20.42 billion in 2025. It is expected to continue growing at a CAGR of 6.23%, reaching USD 27.61 billion by 2030.

The bronchodilators landscape stands at a pivotal crossroads, driven by evolving patient needs, regulatory reforms, and rapid scientific breakthroughs. As respiratory disorders such as asthma and COPD continue to impose a substantial burden on healthcare systems worldwide, industry stakeholders must navigate a complex matrix of technological innovations, shifting reimbursement paradigms, and escalating patient expectations. This executive summary frames the current dynamics shaping the bronchodilators market, highlights critical inflection points, and sets the stage for a strategic deep dive into market drivers, segment behavior, and actionable pathways. By leveraging data-driven insights and expert analysis, decision-makers can align their portfolios with emerging opportunities, mitigate operational risks, and foster sustainable growth in an increasingly competitive arena.

Transformative Shifts Reshaping the Bronchodilators Landscape

Over the past decade, the bronchodilators sector has experienced transformative shifts propelled by precision medicine, digital health integration, and an intensified focus on patient-centric care. Technological advances in inhalation devices-ranging from smart nebulizers with real-time adherence monitoring to next-generation dry powder inhalers-are redefining therapeutic delivery. Concurrently, clinical research has ushered in novel molecules targeting specific receptor subtypes, bolstering efficacy while minimizing systemic side effects. Reimbursement landscapes have also evolved: payers increasingly favor value-based contracts that link outcomes to cost, incentivizing manufacturers to demonstrate real-world effectiveness through robust evidence generation.

Moreover, the rise of telemedicine and remote patient monitoring has extended the continuum of care beyond clinic walls, enabling early intervention and personalized dosing adjustments. This convergence of scientific innovation, digital engagement, and payment reform signals a paradigm shift: bronchodilator therapies are no longer evaluated solely on pharmacological potency but on holistic patient experience and long-term health economics impact.

Cumulative Impact of United States Tariffs in 2025

In 2025, newly implemented United States tariffs on select pharmaceutical components have introduced additional cost pressures across the bronchodilators supply chain. Import duties on specialized excipients and inhaler propellants have elevated manufacturing overhead, prompting some producers to explore localized sourcing or vertical integration. As a result, formulation costs have surged, leading to strategic price adjustments in downstream markets.

At the same time, companies have accelerated negotiations with key suppliers to secure long-term contracts that hedge against tariff volatility. These measures, combined with targeted process optimization and lean manufacturing initiatives, have helped mitigate margin erosion. Nevertheless, the tariff environment underscores the importance of supply chain resilience, regulatory agility, and proactive stakeholder collaboration to preserve market competitiveness.

Key Segmentation Insights Across Multiple Dimensions

A granular examination of market dynamics reveals that product type differentiation drives both clinical adoption and investment focus. Long-acting anticholinergics and beta-2 agonists have captured greater share due to their favorable dosing profiles, while combination therapies pairing beta-2 agonists with anticholinergics or corticosteroids continue to gain traction among patients with moderate to severe respiratory conditions.

Turning to dosage form segmentation, inhalation platforms-particularly dry powder and metered-dose inhalers-dominate market consumption, complemented by nebulizers in acute care settings, injectable solutions for emergency interventions, and oral tablets for adjunctive therapy. Within application segments, asthma management remains a core growth area, but COPD treatment-split between chronic bronchitis and emphysema subpopulations-commands significant therapeutic investment. Exercise-induced bronchoconstriction and allergic reaction use cases further diversify the application landscape.

From an end-user perspective, hospitals, whether public or private, serve as primary channels for severe-case interventions, while clinics and homecare settings address maintenance therapy and patient self-management. Distribution channels spanning drug stores, hospital pharmacies, online pharmacies, and retail outlets illustrate evolving consumer preferences, with digital and omnichannel strategies supporting broader access.

Patient demographics further inform segmentation strategies: adults, geriatrics, and pediatric populations exhibit distinct safety and adherence considerations, while comorbidities such as diabetes, hypertension, and obesity necessitate tailored dosing regimens. Gender-specific response profiles also influence product formulation and marketing.

Mechanism of action differentiation underscores the scientific complexity of the market, encompassing adrenergic receptor agonists, muscarinic receptor antagonists, and phosphodiesterase inhibitors. Finally, research and development priorities-ranging from biologic therapies and genomic medicine in emerging pipelines to ongoing clinical trials-highlight the sustained commitment to next-generation bronchodilator innovation.

Key Regional Insights Influencing Market Priorities

Regional dynamics play a critical role in shaping opportunity priorities. In the Americas, robust healthcare infrastructure, comprehensive insurance coverage, and established regulatory frameworks accelerate technology adoption, particularly in advanced inhalation devices. Meanwhile, cost-containment pressures drive a competitive generics market, prompting brand-name manufacturers to differentiate through patient support programs and outcomes data.

Europe, Middle East & Africa present a heterogeneous landscape: Western Europe exhibits strong public funding for chronic respiratory disease management, whereas Middle Eastern markets emphasize localized partnerships to expand care access. In Africa, infrastructure limitations necessitate innovative distribution models and community health initiatives to reach underserved populations.

The Asia-Pacific region offers a compelling growth trajectory fueled by rising prevalence of air pollution-related respiratory conditions, expanding middle-class healthcare spending, and government incentives for domestic manufacturing. However, fragmented regulatory processes and variable reimbursement policies require agile market entry strategies and adaptive pricing models.

Key Company Insights Driving Innovation and Collaboration

A cadre of diversified players is driving innovation, strategic alliances, and portfolio expansion across the bronchodilators sector. Multinational leaders like AstraZeneca PLC, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. leverage extensive R&D pipelines and global distribution networks to maintain market leadership. At the same time, niche specialists such as AdvaCare Pharma, AMGIS Lifescience Ltd., Cambrex Corporation, Catalent, Inc., and Prasco Laboratories focus on formulation expertise and contract development services, catering to both emerging and established brands.

Indian-based firms including Cipla Limited, Glenmark Pharmaceuticals Limited, Lupin Limited, Mylan Inc. by Viatris Inc., Sun Pharmaceutical Industries Limited, and Zydus Group compete on cost efficiency and broad generic portfolios, capturing significant volume in price-sensitive markets. Regional innovators like Hikma Pharmaceuticals PLC and Nephron Pharmaceuticals Corporation address specialized inhalation therapies, while high-tech service providers such as Siemens Healthcare GmbH, Steris Healthcare Pvt. Ltd., and Thermo Fisher Scientific Inc. supply upstream equipment and analytical solutions crucial for manufacturing scale-up.

Finally, dedicated inhalation specialists Vectura Group PLC and Ralington Pharma LLP, alongside integrated pharmaceutical conglomerates like Perrigo Company PLC, continue to advance inhaled biologic and device combinations, reflecting an industry-wide push toward differentiated delivery systems and patient adherence technologies.

Actionable Recommendations for Industry Leaders

To capitalize on emerging opportunities, industry leaders should prioritize three strategic imperatives. First, accelerate investment in smart delivery platforms that integrate digital monitoring with drug formulation. By partnering with technology firms and leveraging real-world evidence, manufacturers can demonstrate value in outcome-based contracts and secure favorable reimbursement.

Second, strengthen supply chain resilience through diversified sourcing and strategic inventory management. Engaging in long-term supplier agreements and adopting advanced analytics for demand forecasting will mitigate the impact of regulatory changes and geopolitical disruptions. In addition, expanding local manufacturing capabilities in high-growth regions can reduce tariff exposure and lead times.

Third, foster collaborative ecosystems that align pharmaceutical, clinical, and payer stakeholders around patient-centric care pathways. Establishing cross-functional initiatives-such as adherence support programs, telehealth services, and community outreach-will enhance health outcomes, expand market access, and reinforce corporate reputation in chronic respiratory disease management.

Conclusion: Navigating the Future of Bronchodilators

The bronchodilators market is undergoing a period of rapid transformation fueled by innovation, regulatory shifts, and changing patient expectations. Navigating this landscape requires a holistic approach that integrates scientific excellence, digital enablement, and supply chain agility. By synthesizing segmentation intelligence, regional nuances, and competitive positioning, stakeholders can craft targeted strategies that drive sustainable growth and deliver meaningful improvements in respiratory care.

Market Segmentation & Coverage

This research report categorizes the Bronchodilators Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Anticholinergics
    • Long-Acting
    • Short-Acting
  • Beta-2 Agonists
    • Long-Acting
    • Short-Acting
  • Combination Therapies
    • Beta-2 Agonists With Anticholinergics
    • Beta-2 Agonists With Corticosteroids
  • Inhalers
    • Dry Powder Inhalers
    • Metered-Dose Inhalers
  • Injectable Solutions
  • Nebulizers
  • Oral Tablets
  • Allergic Reactions
  • Asthma
  • COPD
    • Chronic Bronchitis
    • Emphysema
  • Exercise-Induced Bronchoconstriction
  • Clinics
  • Homecare Settings
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Age Group
    • Adults
    • Geriatric
    • Pediatric
  • Comorbid Conditions
    • Diabetes
    • Hypertension
    • Obesity
  • Gender
    • Female
    • Male
  • Adrenergic Receptor Agonists
  • Muscarinic Receptor Antagonists
  • Phosphodiesterase Inhibitors
  • Emerging Therapies
    • Biologic Therapies
    • Genomic Medicine
  • Ongoing Clinical Trials

This research report categorizes the Bronchodilators Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bronchodilators Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AdvaCare Pharma
  • AMGIS Lifescience Ltd.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Siemens Healthcare GmbH
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Vectura Group PLC
  • Zydus Group

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bronchodilators Market, by Product Type
8.1. Introduction
8.2. Anticholinergics
8.2.1. Long-Acting
8.2.2. Short-Acting
8.3. Beta-2 Agonists
8.3.1. Long-Acting
8.3.2. Short-Acting
8.4. Combination Therapies
8.4.1. Beta-2 Agonists With Anticholinergics
8.4.2. Beta-2 Agonists With Corticosteroids
9. Bronchodilators Market, by Dosage Form
9.1. Introduction
9.2. Inhalers
9.2.1. Dry Powder Inhalers
9.2.2. Metered-Dose Inhalers
9.3. Injectable Solutions
9.4. Nebulizers
9.5. Oral Tablets
10. Bronchodilators Market, by Application
10.1. Introduction
10.2. Allergic Reactions
10.3. Asthma
10.4. COPD
10.4.1. Chronic Bronchitis
10.4.2. Emphysema
10.5. Exercise-Induced Bronchoconstriction
11. Bronchodilators Market, by End-User
11.1. Introduction
11.2. Clinics
11.3. Homecare Settings
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Bronchodilators Market, by Distribution Channel
12.1. Introduction
12.2. Drug Stores
12.3. Hospital Pharmacies
12.4. Online Pharmacies
12.5. Retail Pharmacies
13. Bronchodilators Market, by Patient Demographics
13.1. Introduction
13.2. Age Group
13.2.1. Adults
13.2.2. Geriatric
13.2.3. Pediatric
13.3. Comorbid Conditions
13.3.1. Diabetes
13.3.2. Hypertension
13.3.3. Obesity
13.4. Gender
13.4.1. Female
13.4.2. Male
14. Bronchodilators Market, by Mechanism of Action
14.1. Introduction
14.2. Adrenergic Receptor Agonists
14.3. Muscarinic Receptor Antagonists
14.4. Phosphodiesterase Inhibitors
15. Bronchodilators Market, by Research and Development
15.1. Introduction
15.2. Emerging Therapies
15.2.1. Biologic Therapies
15.2.2. Genomic Medicine
15.3. Ongoing Clinical Trials
16. Americas Bronchodilators Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Bronchodilators Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Bronchodilators Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AdvaCare Pharma
19.3.2. AMGIS Lifescience Ltd.
19.3.3. AstraZeneca PLC
19.3.4. Boehringer Ingelheim International GmbH
19.3.5. Cambrex Corporation
19.3.6. Catalent, Inc.
19.3.7. Cipla Limited
19.3.8. GlaxoSmithKline PLC
19.3.9. Glenmark Pharmaceuticals Limited
19.3.10. Hikma Pharmaceuticals PLC
19.3.11. Lupin Limited
19.3.12. Mylan Inc. by Viatris Inc.
19.3.13. Nephron Pharmaceuticals Corporation
19.3.14. Novartis AG
19.3.15. Perrigo Company PLC
19.3.16. Pfizer Inc.
19.3.17. Prasco Laboratories
19.3.18. Ralington Pharma LLP
19.3.19. Siemens Healthcare GmbH
19.3.20. Steris Healthcare Pvt. Ltd.
19.3.21. Sun Pharmaceutical Industries Limited
19.3.22. Teva Pharmaceutical Industries Ltd.
19.3.23. Thermo Fisher Scientific Inc.
19.3.24. Vectura Group PLC
19.3.25. Zydus Group
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. BRONCHODILATORS MARKET MULTI-CURRENCY
FIGURE 2. BRONCHODILATORS MARKET MULTI-LANGUAGE
FIGURE 3. BRONCHODILATORS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRONCHODILATORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS WITH ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS WITH CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRONCHODILATORS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRONCHODILATORS MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRONCHODILATORS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRONCHODILATORS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRONCHODILATORS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRONCHODILATORS MARKET SIZE, BY ALLERGIC REACTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRONCHODILATORS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRONCHODILATORS MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRONCHODILATORS MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRONCHODILATORS MARKET SIZE, BY EXERCISE-INDUCED BRONCHOCONSTRICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRONCHODILATORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRONCHODILATORS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRONCHODILATORS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRONCHODILATORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRONCHODILATORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRONCHODILATORS MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRONCHODILATORS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRONCHODILATORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRONCHODILATORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BRONCHODILATORS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BRONCHODILATORS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BRONCHODILATORS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BRONCHODILATORS MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BRONCHODILATORS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BRONCHODILATORS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BRONCHODILATORS MARKET SIZE, BY ADRENERGIC RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BRONCHODILATORS MARKET SIZE, BY MUSCARINIC RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BRONCHODILATORS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BRONCHODILATORS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BRONCHODILATORS MARKET SIZE, BY GENOMIC MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BRONCHODILATORS MARKET SIZE, BY ONGOING CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 127. CANADA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. CANADA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 130. CANADA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 131. CANADA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. CANADA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 133. CANADA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. CANADA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 135. CANADA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. CANADA BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 137. CANADA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. CANADA BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 139. CANADA BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. CANADA BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 141. CANADA BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 142. CANADA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. CANADA BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 144. CANADA BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. CHINA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. CHINA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 221. CHINA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 222. CHINA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 223. CHINA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 224. CHINA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 225. CHINA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. CHINA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 227. CHINA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. CHINA BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. CHINA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. CHINA BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. CHINA BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 232. CHINA BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 233. CHINA BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 234. CHINA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. CHINA BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 236. CHINA BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 237. INDIA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. INDIA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 239. INDIA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 240. INDIA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 241. INDIA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 242. INDIA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 243. INDIA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. INDIA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 245. INDIA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. INDIA BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 247. INDIA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. INDIA BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 249. INDIA BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 250. INDIA BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 251. INDIA BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 252. INDIA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. INDIA BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 254. INDIA BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. JAPAN BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 275. JAPAN BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 276. JAPAN BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 277. JAPAN BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. JAPAN BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 279. JAPAN BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. JAPAN BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 281. JAPAN BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. JAPAN BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 283. JAPAN BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. JAPAN BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 285. JAPAN BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. JAPAN BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 287. JAPAN BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 288. JAPAN BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 290. JAPAN BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 317. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 318. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 319. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 320. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 321. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 322. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 323. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 324. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 325. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 327. SINGAPORE BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. SINGAPORE BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 329. SINGAPORE BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 330. SINGAPORE BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 331. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 332. SINGAPORE BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 333. SINGAPORE BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 334. SINGAPORE BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 335. SINGAPORE BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 336. SINGAPORE BRONCHODILATORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 337. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. SINGAPORE BRONCHODILATORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 339. SINGAPORE BRONCHODILATORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 340. SINGAPORE BRONCHODILATORS MARKET SIZE, BY COMORBID CONDITIONS, 2018-2030 (USD MILLION)
TABLE 341. SINGAPORE BRONCHODILATORS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE BRONCHODILATORS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE BRONCHODILATORS MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 349. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 350. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 351. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 352. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY COPD, 2018-2030 (USD MILLION)
TABLE 353. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 354. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY HOSPITALS

Companies Mentioned

  • AdvaCare Pharma
  • AMGIS Lifescience Ltd.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Siemens Healthcare GmbH
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Vectura Group PLC
  • Zydus Group

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bronchodilators Market by Drug Class, Route of Administration, Disease, End-users - Global Forecast 2025-2030 - Product Image

Bronchodilators Market by Drug Class, Route of Administration, Disease, End-users - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Bronchodilators - Global Strategic Business Report - Product Image

Bronchodilators - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Bronchitis Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Bronchitis Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global, United States Global, United States
From
Bronchodilators Market Report by Indication, Drug Type, Route of Administration, and Region 2024-2032 - Product Image

Bronchodilators Market Report by Indication, Drug Type, Route of Administration, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Bronchodilators Market Report 2025 - Product Image

Bronchodilators Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.